Clinical Trials
14 trialsNCT04307134 2025-12-31
Besponsa Post Marketing Surveillance Study
Pfizer
Completed
NCT05687032 2025-12-03
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Pfizer
Phase 4 Completed
NCT05597085 2025-02-04
A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment
Pfizer
Completed
NCT03677596 2023-11-22
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients
Pfizer
Phase 4 Completed
NCT04456959 2022-09-28
InO
Pfizer
Completed
NCT01055496 2019-08-02
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Pfizer
Phase 1 Completed
NCT00724971 2019-03-15
Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab
Pfizer
Phase 1 Completed
NCT01564784 2019-01-09
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Pfizer
Phase 3 Completed
NCT00073749 2018-12-17
Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
Pfizer
Phase 1 Completed
NCT00299494 2018-03-08
Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
Pfizer
Phase 1/2 Completed
NCT00867087 2017-12-05
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Pfizer
Phase 2 Completed
NCT00868608 2017-10-31
Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
Pfizer
Phase 2 Completed
NCT01363297 2017-04-13
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
Pfizer
Phase 2 Completed
NCT00717925 2015-12-09
Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 1 Completed